Search
Selected Filter
Filter Results
Displaying 121–130 of 199 research results for “stem-cells”
-
May 16, 2024
No serious adverse events were reported. One patient had encouraging improvement in retinal sensitivity.
-
May 2, 2024
Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial
The XLRS gene therapy was well tolerated and resolved damaging schisis cavities in patients receiving the lowest dose.
-
Apr 30, 2024
Usher Syndrome Research Advances
Recent developments in research on Usher Syndrome.
-
Apr 8, 2024
Ocugen to Launch Phase 3 Clinical Trial of Modifier Gene Therapy for RP
The emerging treatment is designed to work independent of the patient’s mutated gene.
-
Jul 28, 2023
Belite Bio Doses First Patient in Phase 3 Clinical Trial for Advanced Dry AMD (GA) Therapy
The company’s emerging, oral treatment is designed to slow vision loss
-
Jul 12, 2023
PYC Doses First Patient in Clinical Trial of RNA Therapy for RP11 (PRPF31 Mutations)
The emerging RNA therapy is designed to boost expression of the PRPF31 protein
-
May 2, 2023
Atsena Receives FDA Authorization to Launch a Gene Therapy Clinical Trial for XLRS
Known as The Lighthouse Study, the Phase ½ trial is expected to begin in mid-2023
-
Feb 18, 2023
Geographic atrophy (GA) is the advanced form of dry age-related macular degeneration (AMD) which causes blindness in one million people in the United States and 5 million worldwide.
This is the first time that a treatment has been approved for this leading cause of blindness.
-
Jan 3, 2023
Opus Genetics Acquires Rights to Gene Therapies for BEST1 and RP (RHO)
The company plans to seek clinical trial authorization for the BEST1 gene therapy during the second half of 2023
-
Dec 2, 2022
SparingVision Receives Authorization to Launch US Clinical Trial for its Cone-Preserving Treatment
The emerging therapy is designed to work independent of the mutated gene causing retinitis pigmentosa